Login

 

GlaxoSmithKline Awarded $63 Million HHS Pact for Pandemic Vaccine Research and Development.

HEALTH AND BEAUTY CLOSE-UP-18 January 2007-GlaxoSmithKline Awarded $63 Million HHS Pact for Pandemic Vaccine Research and Development(C)2007 - CloseUpMedia - newsdesk@closeupmedia.com

GlaxoSmithKline, one of the world's largest vaccine manufacturers, has been awarded a contract from the

U.S. Department of Health and Human Services (HHS) for the development of pre-pandemic and pandemic flu vaccines.

With a value of at least $63.3 million, the contract supports GSK's ongoing pandemic vaccine research in using the company's adjuvant technology in combination with antigens to induce a strong immune response.

Under the terms of the contract, GSK will engage in research and development leading towards licensure of antigen-sparing pre-pandemic and pandemic vaccines with adjuvant that will help the U.S. Government extend the limited North American supply of pandemic flu vaccines to protect larger populations in the event of a flu pandemic. The 5-year contract also gives the U.S. Government the option to fund an additional $44 million of future clinical development programs related to antigen-sparing pandemic vaccines.

"A limited global supply capacity of flu antigen makes it critical that we use innovative adjuvant system technology to produce a new generation of flu pandemic vaccines," said David Stout, President of Pharmaceuticals at GlaxoSmithKline. "GSK's research in adjuvant technology over the past two decades uniquely positions our company to develop adjuvants designed to boost immune response and give broader protection while using smaller amounts of antigen. This award leverages our adjuvant expertise, and supports GSK's short and long-term vision of helping governments around the world in their pandemic preparedness efforts."In a separate action related to pandemic preparedness GSK also announced that the company has begun shipping up to 15.5 million treatment courses of its antiviral Relenza (zanamivir for inhalation). The Relenza shipments are part of GSK's agreement with the Federal Government announced last year to provide the U.S. Government and the states with Relenza for building their flu pandemic stockpiles. GSK also has started to ship Relenza to retail pharmacies to fulfill patient prescriptions for seasonal flu treatment and prevention, the company noted in a release.

((Comments on this story may be sent to newsdesk@closeupmedia))((Distributed via M2 Communications Ltd - http://www.m2.com))

T T T
Print icon - email article Email this Article icon - digg  Digg It icon - del.icio.us  del.icio.us

Related Articles

  • Vaccine against three kinds of HIV begins human tests.
    • The new Vaccine Research Center at the U.S. National Institute of Allergy and Infectious Diseases is starting the first human trial of its vaccine candidate, developed to target HIV clades (subtypes) A, B, and C. Together these subtypes are responsible ......
  • Prepare for the worst.
    • Byline: The Register-Guard A good way to become very afraid very fast is to spend just a few minutes glancing down a list of potential consequences should the H5N1 bird flu virus mutate to a form easily passed from person ......
  • Influenza Vaccines Given Intranasally Equally Effective.
    • Children who received influenza vaccines from three different lots of a cold-adapted intranasal vaccine were equally well protected from the flu, said Dr. Kenneth M. Zangwill of the University of California Los Angeles Center for Vaccine Research, Torrance, and his ......
  • Pandemic awareness training.
    • ToucanEd also offers pandemic awareness training courses that vary from four hours to two days for employees, students, or public audiences to keep your organization running in the event of pandemic flu. The training deals with important measures you can ......
  • HPV vaccination plan hindered by STD stigma, ignorance.
    • WASHINGTON -- Without a thorough public education program, ignorance and stigma could stymie any future attempts to vaccinate Americans against human papillomavirus. "Having a vaccine available doesn't necessarily mean the public will utilize it," Allison Friedman said at a conference ......
  • Vaccine: no link to neonatal death.
    • The hepatitis B vaccine (HBV) was not a factor in neonatal death in a study of 1,363 children, said Eileen M Eriksen of the University of California, Los Angeles, Center for Vaccine Research, Torrance, Calif., and her associates. The researchers ......
  • If you offer an HPV vaccine, will they come?
    • WASHINGTON -- Without a thorough public education program, ignorance and stigma could stymie any future attempts to vaccinate Americans against human papillomavirus. "Having a vaccine available doesn't necessarily mean the public will utilize it," Allison Friedman said at a conference ......
  • Fellowship boosts Vaccine research.
    • [ILLUSTRATION OMITTED] Research into the development of vaccines against life-threatening bacterial diseases has been boosted by a $4 million fellowship. University of Adelaide infectious diseases expert professor James Paton is one of nine medical researchers to receive an Australia Fellowship ......
  • If you offer an HPV vaccine, will patients want to get it?
    • WASHINGTON -- Without a thorough public education program, ignorance and stigma could stymie any future attempts to vaccinate Americans against human papillomavirus. "Having a vaccine available doesn't necessarily mean the public will utilize it," Allison Friedman said at a conference ......
  • Tat inhibitors, a new approach: interview with Olaf Kutsch, Ph.D.
    • Years ago Hoffmann-LaRoche (now Roche) developed an experimental drug that blocked the HIV protein Tat in laboratory tests. But it did not work against HIV in patients, for reasons that were then unknown. Though scientists considered this kind of antiretroviral ......
  • HHS expands vaccine capacity.
    • The Department of Health and Human Services has awarded two contracts to expand the domestic influenza vaccine manufacturing capacity that could be used in the event of a influenza pandemic. The 5-year contracts were awarded to Sanofi Pasteur ($77.4 million) ......
  • HHS expands vaccine capacity.
    • The Department of Health and Human Services has awarded two contracts to expand the domestic influenza vaccine manufacturing capacity that could be used in the event of a potential influenza pandemic. The 5-year contracts were awarded to Sanofi Pasteur ($77.4 ......
  • HPV vaccine: if you have it, will they come? Insurance coverage may up acceptance.
    • WASHINGTON -- Without a thorough public education program, ignorance and stigma could stymie any future attempts to vaccinate Americans against human papillomavirus. "Having a vaccine available doesn't necessarily mean the public will utilize it," Allison Friedman said at a conference ......
  • If the HPV vaccine ever becomes available, will patients want to get it?
    • WASHINGTON -- Without a thorough public education program, ignorance and stigma could stymie any future attempts to vaccinate Americans against human papillomavirus. "Having a vaccine available doesn't necessarily mean the public will utilize it," Allison Friedman said at a conference ......
  • Preparing for pandemic.
    • Byline: The Register-Guard Nothing has the potential to save more lives in a global flu pandemic than the ability to quickly produce an effective vaccine. President Bush has appropriately made vaccine development the cornerstone of his $7.1 billion plan to ......

Related Topics

Subject: 
Industries: 
Location: 
Site Map | Contact Us | About Us

Copyright © 1999 - 2009 AllBusiness.com Inc. All rights Reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Copyright 2009 The Gale Group, Inc. All rights reserved.
© COPYRIGHT 2007 M2 Communications Ltd.


You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.

Get In-Depth Company Information from Hoover's | Buy a D&B Credit Report | What is in Your Company's D&B Credit Report? | Online Business Database
Online Business Information | Email Marketing Lists | Sales and Marketing Solutions | Business Mailing Lists | AllBusiness.com